DrugPatentWatch Database Preview
TYGACIL Drug Profile
Email this page to a colleague
» See Plans and PricingWhich patents cover Tygacil, and when can generic versions of Tygacil launch?
Tygacil is a drug marketed by Pf Prism Cv and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-two patent family members in twenty-nine countries.
The generic ingredient in TYGACIL is tigecycline. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the tigecycline profile page.
US ANDA Litigation and Generic Entry Outlook for Tygacil
A generic version of TYGACIL was approved as tigecycline by SANDOZ INC on May 27th, 2015.
Summary for TYGACIL
| International Patents: | 62 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 79 |
| Clinical Trials: | 5 |
| Patent Applications: | 1,863 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TYGACIL |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TYGACIL |
| DailyMed Link: | TYGACIL at DailyMed |
Recent Clinical Trials for TYGACIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | N/A |
| Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
Pharmacology for TYGACIL
| Drug Class | Tetracycline-class Antibacterial |
US Patents and Regulatory Information for TYGACIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | AP | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | AP | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | AP | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TYGACIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | Start Trial | Start Trial |
| Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | Start Trial | Start Trial |
| Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TYGACIL
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 057649 | Start Trial |
| Argentina | 109500 | Start Trial |
| South Africa | 200707831 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TYGACIL
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0536515 | 91279 | Luxembourg | Start Trial | 91279, EXPIRES: 20170821 |
| 0536515 | SPC/GB06/033 | United Kingdom | Start Trial | PRODUCT NAME: TIGECYCLINE |
| 0536515 | CA 2006 00027 | Denmark | Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
